SCHEMBL16639344

SCHEMBL16639344

Cc1ccccc1-c1ccc2oc3ccc4c(-c5ccccc5C)ccc5oc6ccc1c2c6-c3c54

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.40
RAB9A P51151 6/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
CASP3 P42574 2/20 0.40
SENP8 Q96LD8 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
SENP6 Q9GZR1 2/20 0.40
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 5/20 0.39
HSD17B10 Q99714 4/20 0.39
HPGD P15428 4/20 0.39
TP53 P04637 2/20 0.39
GAA P10253 1/20 0.39
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KCNA3 P22001 2/20 0.36
TSHR P16473 4/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10028108 0.86 CYP1A2 (0.46) SMN1; SMN2KDM4EALDH1A1HSD17B10HPGD
SCHEMBL16801034 0.84 SMN1; SMN2 (0.41) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL16639345 0.81 MAPT (0.40) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL16659630 0.79 TDP2 (0.34) ESR1ESR2
SCHEMBL10028109 0.79 WEE1 (0.40) NPC1RAB9AKDM4EALDH1A1HSD17B10
SCHEMBL10028105 0.79 MAOA (0.43) KDM4EALDH1A1HSD17B10HPGDTP53
SCHEMBL10028198 0.78 WEE1 (0.41) NPC1RAB9AKDM4EALDH1A1USP2
SCHEMBL21726246 0.77 SMN1; SMN2 (0.36) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL10028111 0.76 WEE1 (0.42) NPC1RAB9AKDM4EALDH1A1USP2
SCHEMBL17241899 0.75 CYP2A6 (0.44) NPC1RAB9ASMN1; SMN2CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150108447-A1 DIOXAANTHANTHRENE COMPOUND AND ELECTRONIC DEVICE SONY CORPORATION (JP) 2015-04-23 US disclosed
US-20150108447-A1 DIOXAANTHANTHRENE COMPOUND AND ELECTRONIC DEVICE SONY CORPORATION (JP) 2015-04-23 US disclosed
US-20150102308-A1 ORGANIC SEMICONDUCTOR LAYER, ELECTRONIC DEVICE, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE SONY CORPORATION (JP) 2015-04-16 US disclosed
US-20150102308-A1 ORGANIC SEMICONDUCTOR LAYER, ELECTRONIC DEVICE, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE SONY CORPORATION (JP) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150108447-A1 DIOXAANTHANTHRENE COMPOUND AND ELECTRONIC DEVICE CYP19A1, CYP1A1, DDT NPC1 4382/4885RAB9A 1974/4885SMN1; SMN2 4695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.